抗体依赖性细胞介导的细胞毒性
髓系白血病
癌症研究
CD33
单克隆抗体
白细胞介素-3受体
免疫学
离体
体内
白血病
髓样
川地34
干细胞
医学
抗体
生物
细胞生物学
生物技术
作者
Samantha J. Busfield,Mark Biondo,M. Wong,Hayley S. Ramshaw,E M Lee,Sukhen C. Ghosh,Hal Braley,Con Panousis,Andrew W. Roberts,Simon He,Danièl Thomas,Louis Fabri,G Vairo,Richard B. Lock,Angel F. López,Andrew D. Nash
出处
期刊:Leukemia
[Springer Nature]
日期:2014-04-07
卷期号:28 (11): 2213-2221
被引量:148
摘要
Acute myeloid leukemia (AML) is a biologically heterogeneous group of related diseases in urgent need of better therapeutic options. Despite this heterogeneity, overexpression of the interleukin (IL)-3 receptor α-chain (IL-3 Rα/CD123) on both the blast and leukemic stem cell (LSC) populations is a common occurrence, a finding that has generated wide interest in devising new therapeutic approaches that target CD123 in AML patients. We report here the development of CSL362, a monoclonal antibody to CD123 that has been humanized, affinity-matured and Fc-engineered for increased affinity for human CD16 (FcγRIIIa). In vitro studies demonstrated that CSL362 potently induces antibody-dependent cell-mediated cytotoxicity of both AML blasts and CD34(+)CD38(-)CD123(+) LSC by NK cells. Importantly, CSL362 was highly effective in vivo reducing leukemic cell growth in AML xenograft mouse models and potently depleting plasmacytoid dendritic cells and basophils in cynomolgus monkeys. Significantly, we demonstrated CSL362-dependent autologous depletion of AML blasts ex vivo, indicating that CSL362 enables the efficient killing of AML cells by the patient's own NK cells. These studies offer a new therapeutic option for AML patients with adequate NK-cell function and warrant the clinical development of CSL362 for the treatment of AML.
科研通智能强力驱动
Strongly Powered by AbleSci AI